Credit Suisse’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-21,390
| Closed | -$321K | – | 4409 |
|
|
2016
Q2 | $321K | Sell |
21,390
-37,613
| -64% | -$483K | ﹤0.01% | 3668 |
|
|
2016
Q1 | $717K | Buy |
59,003
+38,990
| +195% | +$547K | ﹤0.01% | 2977 |
|
|
2015
Q4 | $319K | Buy |
20,013
+3,422
| +21% | +$53.9K | ﹤0.01% | 3659 |
|
|
2015
Q3 | $255K | Sell |
16,591
-32,031
| -66% | -$692K | ﹤0.01% | 3806 |
|
|
2015
Q2 | $1.18M | Buy |
48,622
+9,816
| +25% | +$235K | ﹤0.01% | 3018 |
|
|
2015
Q1 | $902K | Sell |
38,806
-24,277
| -38% | -$643K | ﹤0.01% | 3061 |
|
|
2014
Q4 | $1.58M | Buy |
63,083
+32,257
| +105% | +$946K | ﹤0.01% | 2747 |
|
|
2014
Q3 | $958K | Sell |
30,826
-2,966
| -9% | -$80.3K | ﹤0.01% | 3085 |
|
|
2014
Q2 | $874K | Sell |
33,792
-435,230
| -93% | -$9.67M | ﹤0.01% | 3410 |
|
|
2014
Q1 | $11M | Sell |
469,022
-585,213
| -56% | -$12.8M | 0.01% | 1180 |
|
|
2013
Q4 | $26.8M | Sell |
1,054,235
-613,296
| -37% | -$13.8M | 0.02% | 682 |
|
|
2013
Q3 | $34M | Sell |
1,667,531
-345,759
| -17% | -$7.7M | 0.03% | 490 |
|
|
2013
Q2 | $42.2M | Buy |
+2,013,290
| New | +$36M | 0.04% | 432 |
|
Credit Suisse's SGNT Position: Q3 2016 in Review
Credit Suisse sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 21,390 shares — an estimated $321K sold.
Credit Suisse first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $42.2M in Q2 2013. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Credit Suisse reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Credit Suisse sold 21,390 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $321K.
- Credit Suisse first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Credit Suisse's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $42.2M in Q2 2013.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Credit Suisse's 13F filing for Q3 2016, filed 15 Nov 2016.